US 11,718,602 B2
EGFR inhibitors
Natasja Brooijmans, Cambridge, MA (US); Jason D. Brubaker, Cambridge, MA (US); John Emmerson Campbell, Cambridge, MA (US); Christopher De Savi, Cambridge, MA (US); Thomas A. Dineen, Cambridge, MA (US); Meredith Suzanne Eno, Cambridge, MA (US); Joseph L. Kim, Cambridge, MA (US); Aysegul Ozen, Cambridge, MA (US); Emanuele Perola, Cambridge, MA (US); Brett D. Williams, Cambridge, MA (US); Douglas Wilson, Cambridge, MA (US); and Kevin J. Wilson, Cambridge, MA (US)
Assigned to Blueprint Medicines Corporation, Cambridge, MA (US)
Filed by Blueprint Medicines Corporation, Cambridge, MA (US)
Filed on Aug. 8, 2022, as Appl. No. 17/883,006.
Application 17/883,006 is a continuation of application No. 17/514,457, filed on Oct. 29, 2021.
Application 17/514,457 is a continuation of application No. PCT/US2020/066629, filed on Dec. 22, 2020.
Claims priority of provisional application 62/953,030, filed on Dec. 23, 2019.
Prior Publication US 2023/0026209 A1, Jan. 26, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. C07D 401/14 (2006.01); A61K 31/506 (2006.01); C07D 471/04 (2006.01); C07D 471/08 (2006.01); C07D 491/048 (2006.01); C07D 491/107 (2006.01); C07D 491/113 (2006.01); C07D 498/08 (2006.01); C07D 519/00 (2006.01)
CPC C07D 401/14 (2013.01) [C07D 471/04 (2013.01); C07D 471/08 (2013.01); C07D 491/048 (2013.01); C07D 491/107 (2013.01); C07D 491/113 (2013.01); C07D 498/08 (2013.01); C07D 519/00 (2013.01); C07B 2200/05 (2013.01); C07B 2200/07 (2013.01)] 8 Claims
 
1. A compound of Formula (II-A):

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt thereof, wherein:
Z is O;
R is H, halogen, or CH3;
Ring A is piperidinyl optionally substituted with 1-6 R1;
each R1 is independently halogen, CN, OH, NRaRb, C1-C4 alkyl, C1-C4 alkoxy, C3-C6 cycloalkyl or —O-C3-C6 cycloalkyl, wherein the alkyl, alkoxy or cycloalkyl represented by R1 or in the group represented by R1 is optionally substituted with 1 to 3 groups selected from deuterium, halogen, OH, NRaRb, C1-C2 alkyl, and C1-C2 alkoxy;
m is 0, 1, 2, 3, 4, 5, or 6;
R2 is H or isopropyl;
R4 is H or methyl;
R5 is H; C1-C4 alkyl optionally substituted with 1 to 3 three groups selected from halogen, CN, and NRaRb; C3-C6 cycloalkyl; or 4-6 membered monocyclic heterocyclyl optionally substituted with C1-C4 alkyl;
R6 is H, CH3, or CH2NH2; and
wherein Ra and Rb are each independently selected from H, methyl and ethyl.